🥇 Sparen vor dem BLACK FRIDAY? Bis zu 55 % auf InvestingPro – schon vor dem großen Tag!JETZT ZUGREIFEN

DGAP-News: Protea Announces Research Collaboration With Oak Ridge National Laboratory / UT-Battelle (deutsch)

Veröffentlicht am 24.02.2012, 12:30
Protea Announces Research Collaboration With Oak Ridge National Laboratory / UT-Battelle

Protea Biosciences, Inc.

24.02.2012 12:30

---------------------------------------------------------------------------

Oak Ridge Installs Protea's LAESI DP-1000 Ionization System

MORGANTOWN, W.Va., 2012-02-24 12:30 CET (GLOBE NEWSWIRE) --

Protea Biosciences Group, Inc. ('Protea'), a leading bioanalytics company,

announced today it had begun a research collaboration with the laboratory of

Gary J. Van Berkel, Ph.D., Distinguished Research Staff and Group Leader,

Organic and Biological Mass Spectrometry Group, in the Chemical Sciences

Division, at Oak Ridge National Laboratory, located in Oak Ridge Tennessee.

Under terms of the research collaboration, a LAESI DP-1000 ionization system,

based on Protea's proprietary technology will be used by the Van Berkel

laboratory to explore the molecular structures of material surfaces. The two

parties will jointly publish research results and Protea will have certain

rights to the discoveries resulting from the collaboration.

Oak Ridge National Laboratory (ORNL) is the largest science and energy national

laboratory in the U.S. Department of Energy system, employing 1600 scientists

and engineers. ORNL's scientific programs focus on materials, neutron science,

energy, high-performance computing, systems biology and national security.

'We are honored to commence this research collaboration with the Van Berkel

laboratory at Oak Ridge,' stated Steve Turner, Protea's Chairman & CEO. 'Their

team has been responsible for many innovations in the field of surface

profiling. We believe the combination of their laboratory's expertise with the

revolutionary capabilities of the LAESI technology will generate exciting

results for life science research.'

Dr. Van Berkel commented, 'There has been a great need for new technology that

ionizes samples with no sample preparation, so that material surfaces can be

analyzed rapidly and without bias under ambient conditions. This product has

the potential to make a real contribution to the future of surface profiling

and imaging mass spectrometry.'

In 2011, Protea completed the development of the first instruments to embody

LAESI technology. By eliminating pretreatment steps, samples can be analyzed

without the possible contamination, bias or sample loss that occurs with the

current techniques, which require the introduction of chemicals,

chromatographic separations, or the destruction of the sample itself, in order

to enable the identification and characterization of material surfaces by mass

spectrometry.

LAESI technology was invented in the laboratory of Akos Vertes, PhD., Professor

of Chemistry, Professor of Biochemistry & Molecular Biology Founder and

Co-director W.M. Keck Institute for Proteomics Technology and Applications

Department of Chemistry, George Washington University, and exclusively licensed

to Protea.

Protea is a leader in the field of Bioanalytics -- the identification and

characterization of proteins, metabolites, and other biomolecules, which are

the products of all living cells and life forms -- technology that is

foundational for all pharmaceutical and life science research.

Forward-Looking Statements

This press release may contain certain statements relating to future results

which are forward-looking statements. These statements are not historical

facts, but instead represent only the Company's belief regarding future events,

many of which, by their nature, are inherently uncertain and outside of the

Company's control. It is possible that the Company's actual results and

financial condition may differ, possibly materially, from the anticipated

results and financial condition indicated in these forward-looking statements.

Further information concerning the Company and its business, including factors

that potentially could materially affect the Company's financial results, are

contained in the Company's filings with the Securities and Exchange Commission.

All forward-looking statements included in this press release are made only as

of the date of this press release, and we do not undertake any obligation to

publicly update or correct any forward-looking statements to reflect events or

circumstances that subsequently occur or of which we hereafter become aware.

CONTACT: Protea Biosciences Group, Inc.

955 Hartman Run Road

Morgantown, WV 26507



Phone: 304.284.2600

Fax: 304.292.7101

stephen.turner@proteabio.com



Protea website: www.proteabio.com

About LAESI: https://proteabio.com/LAESI

Oak Ridge National Laboratory website: www.ornl.gov/

News Source: NASDAQ OMX

24.02.2012 Dissemination of a Corporate News, transmitted by DGAP -

a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------



Language: English

Company: Protea Biosciences, Inc.





United States

Phone:

Fax:

E-mail:

Internet:

ISIN: US9900524250

WKN:



End of Announcement DGAP News-Service



---------------------------------------------------------------------------

Aktuelle Kommentare

Installieren Sie unsere App
Risikohinweis: Beim Handel mit Finanzinstrumenten und/oder Kryptowährungen bestehen erhebliche Risiken, die zum vollständigen oder teilweisen Verlust Ihres investierten Kapitals führen können. Die Kurse von Kryptowährungen unterliegen extremen Schwankungen und können durch externe Einflüsse wie finanzielle, regulatorische oder politische Ereignisse beeinflusst werden. Durch den Einsatz von Margin-Trading wird das finanzielle Risiko erhöht.
Vor Beginn des Handels mit Finanzinstrumenten und/oder Kryptowährungen ist es wichtig, die damit verbundenen Risiken vollständig zu verstehen. Es wird empfohlen, sich gegebenenfalls von einer unabhängigen und sachkundigen Person oder Institution beraten zu lassen.
Fusion Media weist darauf hin, dass die auf dieser Website bereitgestellten Kurse und Daten möglicherweise nicht in Echtzeit oder vollständig genau sind. Diese Informationen werden nicht unbedingt von Börsen, sondern von Market Makern zur Verfügung gestellt, was bedeutet, dass sie indikativ und nicht für Handelszwecke geeignet sein können. Fusion Media und andere Datenanbieter übernehmen daher keine Verantwortung für Handelsverluste, die durch die Verwendung dieser Daten entstehen können.
Die Nutzung, Speicherung, Vervielfältigung, Anzeige, Änderung, Übertragung oder Verbreitung der auf dieser Website enthaltenen Daten ohne vorherige schriftliche Zustimmung von Fusion Media und/oder des Datenproviders ist untersagt. Alle Rechte am geistigen Eigentum liegen bei den Anbietern und/oder der Börse, die die Daten auf dieser Website bereitstellen.
Fusion Media kann von Werbetreibenden auf der Website aufgrund Ihrer Interaktion mit Anzeigen oder Werbetreibenden vergütet werden.
Im Falle von Auslegungsunterschieden zwischen der englischen und der deutschen Version dieser Vereinbarung ist die englische Version maßgeblich.
© 2007-2024 - Fusion Media Limited. Alle Rechte vorbehalten.